About CuraSen Therapeutics
CuraSen Therapeutics is a private company based in San Carlos, California. It has reported $68,635,010 raised in four offerings on Form D since January 2019. Its chief executive is Anthony Ford.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Aug 26, 2024 | Sep 18, 2024 | $5,785,019of $45.6M target | 7 | $826K | EquityRule 506(b) | Form D ↗ |
| Nov 1, 2022 | Nov 10, 2022amended Oct 12, 2023 | $17,599,997of $20.8M target | 11 | $1.5M | EquityRule 506(b) | Form D/A ↗1 earlier filing |
| Oct 21, 2021 | Nov 5, 2021 | $18,000,000fully sold | 10 | $1.8M | EquityRule 506(b) | Form D ↗ |
| Sep 18, 2018 | Jan 25, 2019 | $27,249,994of $54.4M target | 10 | $2.7M | EquityRule 506(c) | Form D ↗ |
| Total, four offerings | $68,635,010 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on CuraSen Therapeutics's Form D filed Sep 18, 2024.
RH
Ron Hunt
Director
AF
Anthony Ford
President and Chief Executive Officer, director
BP
Benjamin Potter
Executive officer
LD
Loretta Tse, Ph.D.
Director
KG
Kathleen Glaub
Director
SD
Simon Tate, Ph.D.
Director
PE
Patrick Enright
Director
Earlier filings also listed Simon Tate (director, last listed Oct 2023), Liam Ratcliffe (director, last listed Jan 2019) and Henry Skinner (director, last listed Jan 2019).